Pipamperone HCl
| Code | Size | Price |
|---|
| TAR-T28417-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28417-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T28417-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Pipamperone acts as an antagonist of the 5-HT2A, 5-HT2B, 5-HT2C D2, D3, D4, α1-adrenergic, and α2-adrenergic receptors. It shows much higher affinity for the 5-HT2A and D4 receptors over the D2 receptor (15-fold in the case of the D4 receptor, and even higher in the case of the 5-HT2A receptor), being regarded as "highly selective" for the former two sites at low doses. Pipamperone has low and likely insignificant affinity for the H1 and mACh receptors, as well as for other serotonin and dopamine receptors.
CAS:
2448-68-2
Formula:
C21H32Cl2FN3O2
Molecular Weight:
448.4
Purity:
0.98
SMILES:
Cl.Cl.NC(=O)C1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)N1CCCCC1
References
1. Boettger S, Kn?pfel S, Schubert M, Garcia Nu?ez D, Plichta MM, Klaghofer R, Jenewein J. Pipamperone and delirium: a preliminary evaluation of its effectiveness in the management of delirium and its subtypes. Swiss Med Wkly. 2017 Jul 27;147:w14471. doi: 10.4414/smw.2017.14471. eCollection 2017 Jul 27. PubMed PMID: 28750419.
2. Tron C, Kloosterboer SM, van der Nagel BCH, Wijma RA, Dierckx B, Dieleman GC, van Gelder T, Koch BCP. Dried Blood Spots Combined With Ultra-High-Performance Liquid Chromatography-Mass Spectrometry for the Quantification of the Antipsychotics Risperidone, Aripiprazole, Pipamperone, and Their Major Metabolites. Ther Drug Monit. 2017 Aug;39(4):429-440. doi: 10.1097/FTD.0000000000000411. PubMed PMID: 28700523.
3. Janus SIM, Reinders GH, van Manen JG, Zuidema SU, IJzerman MJ. Psychotropic Drug-Related Fall Incidents in Nursing Home Residents Living in the Eastern Part of The Netherlands. Drugs R D. 2017 Jun;17(2):321-328. doi: 10.1007/s40268-017-0181-0. PubMed PMID: 28389998; PubMed Central PMCID: PMC5427052.
4. Paulzen M, Schoretsanitis G, Stegmann B, Hiemke C, Gr?nder G, Schruers KRJ, Walther S, Lammertz SE, Haen E. Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 2;76:101-106. doi: 10.1016/j.pnpbp.2017.03.002. Epub 2017 Mar 14. PubMed PMID: 28302501.